abstract OBJECTIVES: Prophylactic vaccination of youngwomen aged 16 to 26 years with the 9-valent (6/11/16/18/31/33/45/52/58) human papillomavirus (HPV) virus-like particle (9vHPV) vaccine prevents infection and disease. We conducted a noninferiority immunogenicity study to bridge the findings in young women to girls and boys aged 9 to 15 years.
WHAT'S KNOWN ON THIS SUBJECT: Prophylactic vaccination of young women 16 to 26 years of age with the 9-valent human papillomavirus (HPV)-like particle (9vHPV) vaccine prevents infection and disease with vaccine HPV types.
WHAT THIS STUDY ADDS:
These data support bridging the efficacy findings with 9vHPV vaccine in young women 16 to 26 years of age to girls and boys 9 to 15 years of age and implementation of gender-neutral HPV vaccination programs in preadolescents and adolescents.
Human papillomavirus (HPV) causes premalignant and malignant lesions of the cervix, 1,2 vagina, 3, 4 vulva, 4, 5 anus, 4, 6 penis, 7 and oropharynx, 8 as well as genital warts. 9, 10 HPV is responsible for ∼5% of the global cancer disease burden. 11 Prophylactic vaccines directed against the 2 most common high-risk HPV types are now widely recommended on the basis of clinical trial results and postlicensure data. 12 The quadrivalent HPV (6/11/16/18) virus-like particle (qHPV) vaccine is highly efficacious in preventing infection and cervical, vaginal, vulvar, and anal dysplasia caused by HPV 6/11/16/18 as well as HPV 6/11-related condyloma, [13] [14] [15] [16] and the bivalent HPV (16/18) vaccine is highly efficacious against HPV 16/18-related infection and cervical dysplasia. 17 Postlicensure studies have shown a rapid decrease in the incidence of high-grade cervical abnormalities, [18] [19] [20] [21] prevalence of vaccine HPV types, [22] [23] [24] [25] [26] and incidence of genital warts [27] [28] [29] [30] [31] in vaccinees. Data have shown that prophylactic HPV vaccination is generally safe and well tolerated. [32] [33] [34] [35] [36] [37] [38] The median age of sexual debut is in the late teens (15-19 years) in most countries. 39 Virginal adolescents (#15 years old) were not included in HPV vaccine efficacy evaluations because of low HPV exposure and ethical constraints. Therefore, qHPV vaccine efficacy findings in subjects aged 16 to 26 years were bridged to subjects aged 9 to 15 years on the basis of the demonstration of noninferior immunogenicity. 40 Current HPV vaccines address ∼70% of cervical cancers via protection from HPV 16/18. Partial crossprotection against nonvaccine HPV types has been reported for both licensed vaccines, although its clinical significance remains uncertain. 41 The 9-valent HPV (6/11/16/18/31/33/ 45/52/58) virus-like particle (9vHPV) vaccine includes 5 additional oncogenic HPV types compared with the qHPV vaccine (HPV 31/33/45/ 52/58), potentially increasing cervical cancer prevention to 90%. 2, 42 The 9vHPV vaccine may also provide increased protection against an extra ∼5% to 10% of vulvar, vaginal, and anal cancers and highgrade vulvar, vaginal, and anal intraepithelial neoplasia. 4, 43, 44 Prophylactic administration of a 3-dose regimen of 9vHPV vaccine to HPV-naive women aged 16 to 26 years is highly efficacious against vaccine HPV type-related infection and disease. 45 In this report we evaluated whether the 9vHPV vaccine induces noninferior serum antibody responses in boys and girls 9 to 15 years of age (the ideal prophylactic HPV vaccination population) compared with adolescent females/women (ie, young women) 16 to 26 years of age (the population used to establish 9vHPV vaccine efficacy).
METHODS

Population
This study (protocol V503-002; NCT00943722) is an international, multicentered immunogenicity and tolerability study in girls and boys (9-15 years of age) who received the 9vHPV vaccine compared with young women (16-26 years of age). The study was initiated in August 2009, and data are current through visits that occurred before or in April 2013. Subjects were enrolled from 72 sites in 17 countries (Austria, Belgium, Brazil, Chile, Colombia, Costa Rica, Finland, India, Peru, Poland, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand and the United States). The study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. An external data monitoring committee assessed safety findings during the study.
The study enrolled 3 cohorts: girls 9 to 15 years of age, boys 9 to 15 years of age, and young women 16 to 26 years of age. For the 2 younger cohorts, participants were required to be generally healthy and sexually naive at enrollment and throughout the vaccination period (through month 7). For the older cohort, participants were required to be generally healthy and have no history of abnormal Papanicolaou test results, no more than 4 lifetime sexual partners, and no previous abnormal cervical biopsy results.
Reasons for exclusions from the study included pregnancy, known allergy to any vaccine component, thrombocytopenia, immunosuppression/previous immunosuppressive therapy, or previous receipt of an HPV vaccine.
Vaccine Dosing
All subjects received 9vHPV vaccine administered (in the deltoid) as a 0.5-mL intramuscular injection. 
Study Design
The study was designed to enroll 1800 girls 9 to 15 years of age, 600 boys 9 to 15 years of age, and 400 young women 16 to 26 years of age. After informed consent and determination that all inclusion criteria and none of the exclusion criteria were met, eligible subjects received an allocation number. An interactive voice response system was used to allocate study subjects and balance randomization between sites. The interactive voice response system assigned the subject an allocation number from 1 of 3 allocation schedules as determined by the sponsor. Subjects, investigators (and staff), laboratory staff, and sponsor were blinded to vaccine lot number.
All subjects were administered a 3-dose regimen of 9vHPV vaccine (day 1, month 2, and month 6). All participants were required to be afebrile (oral temperature ,37.8°C) within 24 hours before each injection. Young women were instructed to use effective contraception through month 7. All female participants underwent pregnancy testing (urine or serum analyses for b-human chorionic gonadotropin) before each vaccination. Participants found to be pregnant were not vaccinated.
All participants were assessed for immunogenicity at day 1 and month 7. In addition, young women 16 to 26 years of age underwent polymerase chain reaction (PCR) testing of cervical and external genital samples at day 1 and month 7 for detection of HPV DNA, including the 9 vaccine types and 5 additional oncogenic HPV types (HPV 35/39/51/56/59). HPV seropositivity at day 1 or PCR positivity at day 1 and month 7 was not a reason for exclusion from the study; however, the results were part of the criteria to define analysis populations.
The study consisted of 2 immunogenicity substudies (Fig 1): (1) an adult-adolescent immunobridging substudy to compare 9vHPV vaccine immunogenicity at month 7 in girls versus young women and boys versus young women and (2) a lot consistency substudy to demonstrate consistent immunogenicity at month 7 in subjects randomly assigned to 3 different vaccine lots of the final manufacturing process.
The lot consistency substudy was conducted in girls. All enrolled girls were randomly assigned equally to 3 vaccine lots (termed lots 1, 2, and 3). Boys and young women did not participate in the lot consistency substudy and were all assigned to lot 1. Girls who were assigned to lot 1 participated in both substudies. This report is focused on the adultadolescent immunobridging substudy, antibody persistence through month 36, and safety. The results of the lot consistency substudy will be published separately.
Assessment
Serum samples obtained at day 1 and month 7 from all subjects and at months 12, 24, and 36 from ∼600 randomly selected girls (random selection made before unblinding) and from all boys were tested for vaccine HPV type antibodies by competitive Luminex immunoassay (cLIA). 46 Participants were observed for 30 minutes after each vaccination for any immediate reaction. All subjects received a vaccination report card (VRC) at the day 1, month 2, and
FIGURE 1
Subject distribution between the adult-adolescent immunobridging substudy and the lot consistency substudy.
FIGURE 2
Disposition of subjects. *One screened, non-randomized subject could not be included in this count because his/her gender was not reported in the database. month 6 study vaccination visits. On the VRC, the subject or (for the 9-to 15-year-olds) the parent/guardian was asked to record the subject's oral temperature in the evening after each study vaccination and daily for 4 days. Also, beginning after each study vaccination and for a total of 15 days, the subject was asked to record injection-site and systemic adverse experiences (AEs) on the VRC. Investigators assigned causality to AEs on the basis of exposure, time course, likely cause, and consistency with the vaccine's known profile. Vaccine-related AEs were determined by the investigator to be possibly, probably, or definitely vaccinerelated. For each AE, participants rated the symptom as mild (awareness of symptom but easily tolerated), moderate (discomfort enough to cause interference with usual activity), or severe (incapacitating with inability to work or do usual activity); injection-site AEs of swelling and erythema were rated by size. Serious AEs were predefined as any AE that resulted in death, were deemed by the investigator to be life-threatening, resulted in a persistent or significant disability or incapacity, resulted in or prolonged an existing in-patient hospitalization, or was a congenital anomaly, a cancer, or an "other important medical event." Serious AEs were collected regardless of causality from day 1 through 6 months after the last vaccination. Deaths and serious vaccine-related AEs were collected throughout the study.
Statistical Methodology
To be included in the immunogenicity analyses, subjects had to meet the following requirements: (1) be seronegative at day 1 and (for 16-to 26-year-old young women) Analyses in a subset of all study sites may be conducted for regulatory purposes. mMU, milli Merck units; N, number of subjects assigned to the respective vaccination group who received at least 1 injection; n, number of subjects contributing to the analysis; The per-protocol immunogenicity (PPI) population included subjects who were seronegative at day 1 (and for young women PCR-negative from day 1 through month 7) to the HPV type being analyzed, who received 3 doses of vaccine during prespecified visit intervals, and from whom the month 7 sample was obtained within a prespecified interval. a The P value for noninferiority was ,.001 for all comparisons. Analyses in a subset of all study sites may be conducted for regulatory purposes.
PCR-negative from day 1 through month 7 only for the HPV type being analyzed (for HPV 6 and HPV 11 immunogenicity analyses, subjects had to be seronegative and PCRnegative for both HPV 6 and HPV 11); (2) receive all 3 doses of the correct clinical material within acceptable day ranges; and (3) have a post-dose 3 serology result within acceptable day ranges.
Noninferiority of month 7 geometric mean titers (GMTs) in girls and boys versus young women (primary immunogenicity objective) was tested by constructing a 95% confidence interval (CI) for the ratio of GMTs. The statistical criterion for noninferiority was established when the lower bound of the 2-sided 95% CI of the GMT ratio (girls:young women or boys:young women) was .0.67 for each HPV type. Separately for each anti-HPV type, the 95% CI of the GMT ratio was derived from an analysis of variance model with the log of antibody titers as the response and vaccination group as the fixed effect. With the planned sample size, this study has .99% power for the primary immunogenicity hypothesis on all 9 HPV types for a true GMT ratio of at least 1.2 for all 9 types. Noninferiority of seroconversion rates in girls and boys versus young women (secondary immunogenicity objective) was based on 9 one-sided tests of noninferiority (1 corresponding to each vaccine HPV type) at the 0.025 level conducted by using the method of Miettinen and Nurminen. 47 The statistical criterion for noninferiority was established when the lower bound of the 2-sided 95% CI for the differences in seroconversion rates (% girls minus % young women or % boys minus % young women) was greater than 25 percentage points for each HPV type.
All subjects who received at least 1 study vaccination and had follow-up data were included in the analysis of safety. Analyses on a subset of all study sites may be conducted for regulatory purposes.
RESULTS
A total of 3111 subjects were screened for inclusion in this study, and 3074 were included in the study from 72 sites. A summary of the number of subjects who were randomly assigned, vaccinated, and completed or discontinued the study is shown in Fig 2. A summary of baseline subject characteristics is provided in Anti-HPV GMTs in girls and boys were highest at month 7 and decreased by ∼70% at month 12 (Table 4) . At months 24 and 36, GMTs were ∼10% to 20% of month 7 GMTs. More than 90% of subjects were seropositive at month 36 for each of the 9 vaccine HPV types ( Table 5 ).
The 3-dose regimen of the 9vHPV vaccine was generally well tolerated , and 58, respectively. N, number of subjects assigned to the respective vaccination group who received at least 1 injection; n, number of subjects with evaluable serology data and who were eligible for the indicated analysis population; The per-protocol immunogenicity (PPI) population included subjects who were seronegative at day 1 (and for young women PCR-negative from day 1 through month 7) to the HPV type being analyzed, who received 3 doses of vaccine during prespecified visit intervals, and from whom the month 7 sample was obtained within a prespecified interval. a The P value for noninferiority was ,.001 for all comparisons.
in each participant group (Table 6) .
Discontinuations from study vaccination due to an AE were rare (1 total). The incidence of serious vaccine-related AEs was low (2 total). The proportions of participants with injection-site or systemic AEs were numerically lower among girls and boys than among young women. The most common (incidence $2%) injection-site AEs were pain, swelling, erythema, and pruritus; most were mild to moderate in intensity. The most common (incidence $2%) vaccine-related systemic AEs among girls and boys were headache and pyrexia. The proportions of participants with a fever ($37.8°C) within 5 days of any injection were comparable between the 3 cohorts ( Table 7) . Five participants (3 girls, 1 boy, and 1 woman) experienced a maximum oral temperature between 39.9°C and 40.9°C. For one of the girls, the fever was deemed not related to the vaccine because it occurred 5 days after vaccination. For the 4 other subjects, fever occurred within 2 days of vaccination and resolved within 1 to 2 days.
Serious AEs by system organ class are shown in Table 8 . One subject died during the study: this subject, a 17-year-old woman at the time of the event, was diagnosed with acute myeloid leukemia 481 days after receiving dose 3. She was hospitalized twice for chemotherapy and died of sepsis 559 days after receiving dose 3, or 7 days after the second round of chemotherapy was initiated. The death was not considered related to the study vaccine. Two serious AEs were judged by the reporting investigator to be vaccine-related. The first, a 10-year-old boy with a previous medical history of seasonal allergy and bronchial asthma experienced an asthma exacerbation 1 day after receiving dose 1, was hospitalized the next day for medical treatment, and fully recovered the following day. The second, a 21-yearold woman, experienced a severe headache on the day she received dose 3; was hospitalized the next day with neck stiffness, headache, and fever (39.0°C); received symptomatic treatment; was diagnosed with viral infection or an AE due to study vaccination; was discharged from the hospital after 2 days; and fully recovered 8 days later. It was noted that she was bitten by a spider 5 days before dose 3 and was still being treated for an infected spider bite when she received dose 3.
A total of 37 participants became pregnant during the course of the study, representing a total of 39 pregnancies. The outcomes of 36 pregnancies were known: 23 resulted in a live birth, and 13 resulted in fetal loss (1 ectopic pregnancy, 2 spontaneous abortions, 1 late fetal death, and 9 elective abortions). One infant was born with a congenital anomaly (unspecified cardiac disease); the estimated date of conception was ∼27 months after dose 3, and the congenital anomaly was considered not related to the study vaccine.
DISCUSSION
This study represents the first analysis of 9vHPV vaccine immunogenicity in girls and boys 9 to 15 years of age, the primary target population for immunoprophylaxis to prevent HPVrelated precancers and cancers of the anogenital tract. Seroconversion for all 9 HPV vaccine types was achieved in .99% of participants in the study. The antibody responses in 9-to 15-yearold boys and girls was shown to be noninferior to those observed in 16-to 26-year-old young women (the population used to establish 9vHPV vaccine efficacy 45 ), thereby supporting the bridging of efficacy findings from 16-to 26-year-old women to 9-to 15-year-old boys and girls. Antibody responses for all vaccine HPV types were numerically greater in girls and boys than in young women. Antibody responses persisted over time, with .90% girls and boys remaining seropositive through 2.5 years after the third vaccination. Administration of 9vHPV vaccine was generally well tolerated in each group.
A limitation of the current study is the lack of clinical efficacy data. Although prophylactic administration of 9vHPV vaccine is highly efficacious against 40 and is consistent with the recommendations from the World Health Organization on prophylactic HPV vaccine development. 48 In other studies, the 9vHPV vaccine and the qHPV vaccine elicited similar anti-HPV 6/11/16/18 responses both in young women aged 16 to 26 years and in girls 9 to 15 years of age. 45, 49 In another study, administration of a 2-dose regimen of qHPV vaccine in girls 9 to 13 years of age induced anti-HPV GMTs that were noninferior to those elicited by administration of a 3-dose regimen in young women 16 to 26 years of age. 50 This finding supports that a 2-dose regimen with the 9vHPV vaccine may be an acceptable alternative, which is currently under study. Another study was conducted to assess the safety of the 9vHPV vaccine in previous recipients of a 3-dose regimen of qHPV vaccine. The 9vHPV vaccine appeared to be generally well tolerated in previous qHPV vaccine recipients (A. Luxembourg, MD, PhD, unpublished results, 2014). The study results will be reported separately.
Follow-up was limited in duration. Duration of protection is particularly relevant to HPV vaccines because individuals remain at risk of HPVrelated disease throughout life. Studies with qHPV vaccine found no evidence of waning immunity in longterm cohorts (through at least 96 months), [51] [52] [53] which suggests that the 9vHPV vaccine could also offer long-term protection. Planned longerterm immunogenicity and effectiveness follow-up of subjects vaccinated with 9vHPV vaccine should provide essential information on durability of protection. In addition, we do not present direct vaccine efficacy data, because those results have already been published. 45 Intensities of pain and itching are defined as follows: mild is an awareness of sign or symptom but easily tolerated; moderate is discomfort enough to cause interference with usual activity; severe is incapacitating with inability to work or do usual activity. c Days 1-15 after any vaccination visit. d The death was not considered by the study investigator to be vaccine-related and was a result of sepsis (occurring 557 days after vaccination dose 3). 
The summaries provided are counts of subjects, and the percentages were calculated relative to the number of subjects with temperature data. N, number of subjects with temperature data who received at least 1 dose of the indicated vaccine. a Days 1-5 after any vaccination visit.
Licensed HPV vaccines have been introduced in the national vaccination programs of .40 countries. 54 Although the age range of the primary target age group varies by country, all of these programs target young adolescents. The 9vHPV vaccine has the potential to provide additional benefit compared with existing vaccines by extending coverage to 5 additional high-risk HPV types. Antibody response to the 9vHPV vaccine in girls and boys aged 9 to 15 years is noninferior to that of young women aged 16 to 26 years, which supports bridging the efficacy findings in young women 16 to 26 years of age to girls and boys 9 to 15 years of age. The 9vHPV vaccine appears to be generally well tolerated in all groups. The 9vHPV vaccine was licensed in 2014 in the United States under the name Gardasil 9 (Merck & Co., Inc, Kenilworth, NJ). Per protocol, serious AEs were reportable regardless of causality from day 1 through 180 days after vaccination dose 3; events of fetal loss were to be reported as serious AEs for any pregnancy with last menstrual period before 180 days after vaccination dose 3; and deaths, and serious vaccine-related AEs, were to be reported for the entire duration of the study. The summaries provided are counts of subjects, and the percentages were calculated relative to the number of subjects as-treated. System organ class categories reported are those with an incidence .0% in any vaccination group. A subject is counted once within a category and may be counted in .1 category. N, number of subjects as-treated who received at least 1 dose of the indicated vaccine and had at least 1 follow-up visit for an AE.
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